Capricor Therapeutics is trading at $8.94, up 6.76%, with no new company-specific announcement identified overnight explaining the September 14, 2026 move.
- Participation in the scheduled H.C. Wainwright Global Investment Conference was previously known and is not a confirmed fresh catalyst.
- Broader markets are lower, so the gain does not clearly track overall sentiment.
- Recent regulatory context remains the extended November 22 PDUFA decision for deramiocel, with no new update explaining the move.